Although ApoA-I plays a central role in reverse cholesterol transport, and contributes to anti-atherosclerotic activity through CEC, therapeutic drugs targeting ApoA-I have not yet to be applied clinically, so we look forward to future developments
New decade, new FDA guidance for diabetes drug development: lessons learned and future directions
Both groups saw comparable weight loss which appeared to be driven by decreased food intake that coincided with rises in plasma drug levels thus indicating there is a PD effect to treatment
In a phase 2 trial investigating the effects of liraglutide in mild Alzheimer's dementia, 204 participants received either liraglutide or placebo for 12 months, with the finding that the liraglutide-treated group had significantly better cognitive function and higher cortical volume compared to control [19]
It operates through both the vagus nerve (direct neural signals) and circulating hormones produced by your gut, fat tissue, and pancreas